Speciality Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Education Dialogues
    • Business Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Speciality Medical Dialogues
    • Editorial
    • News
        • Anesthesiology
        • Cancer
        • Cardiac Sciences
        • Critical Care
        • Dentistry
        • Dermatology
        • Diabetes and Endo
        • Diagnostics
        • ENT
        • Featured Research
        • Gastroenterology
        • Geriatrics
        • Medicine
        • Nephrology
        • Neurosciences
        • Nursing
        • Obs and Gynae
        • Ophthalmology
        • Orthopaedics
        • Paediatrics
        • Parmedics
        • Pharmacy
        • Psychiatry
        • Pulmonology
        • Radiology
        • Surgery
        • Urology
    • Practice Guidelines
        • Anesthesiology Guidelines
        • Cancer Guidelines
        • Cardiac Sciences Guidelines
        • Critical Care Guidelines
        • Dentistry Guidelines
        • Dermatology Guidelines
        • Diabetes and Endo Guidelines
        • Diagnostics Guidelines
        • ENT Guidelines
        • Featured Practice Guidelines
        • Gastroenterology Guidelines
        • Geriatrics Guidelines
        • Medicine Guidelines
        • Nephrology Guidelines
        • Neurosciences Guidelines
        • Obs and Gynae Guidelines
        • Ophthalmology Guidelines
        • Orthopaedics Guidelines
        • Paediatrics Guidelines
        • Psychiatry Guidelines
        • Pulmonology Guidelines
        • Radiology Guidelines
        • Surgery Guidelines
        • Urology Guidelines
    LoginRegister
    Speciality Medical Dialogues
    LoginRegister
    • Home
    • Editorial
    • News
      • Anesthesiology
      • Cancer
      • Cardiac Sciences
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endo
      • Diagnostics
      • ENT
      • Featured Research
      • Gastroenterology
      • Geriatrics
      • Medicine
      • Nephrology
      • Neurosciences
      • Nursing
      • Obs and Gynae
      • Ophthalmology
      • Orthopaedics
      • Paediatrics
      • Parmedics
      • Pharmacy
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
    • Practice Guidelines
      • Anesthesiology Guidelines
      • Cancer Guidelines
      • Cardiac Sciences Guidelines
      • Critical Care Guidelines
      • Dentistry Guidelines
      • Dermatology Guidelines
      • Diabetes and Endo Guidelines
      • Diagnostics Guidelines
      • ENT Guidelines
      • Featured Practice Guidelines
      • Gastroenterology Guidelines
      • Geriatrics Guidelines
      • Medicine Guidelines
      • Nephrology Guidelines
      • Neurosciences Guidelines
      • Obs and Gynae Guidelines
      • Ophthalmology Guidelines
      • Orthopaedics Guidelines
      • Paediatrics Guidelines
      • Psychiatry Guidelines
      • Pulmonology Guidelines
      • Radiology Guidelines
      • Surgery Guidelines
      • Urology Guidelines
    • Home
    • Practice Guidelines
    • Featured Practice Guidelines
    • AIIMS guidance on...

    AIIMS guidance on management of Acute Febrile Illness

    Written by Dr. Kamal Kant Kohli Kohli Published On 2019-12-02T19:00:32+05:30  |  Updated On 9 Aug 2021 5:01 PM IST

    All India Institute of Medical Sciences, Delhi has released AIIMS Antibiotics Policy which has been prepared by the Department of Medicine with Multidisciplinary collaboration. The guidance for Febrile illness and Sepsis includes guidance on Acute Febrile Illness the salient features of which are hereunder.


    Acute Febrile Illness (AFI): Refers to patients presenting with acute onset fever ( >= 38.3'C or >=101'F) lasting for more than 2 days but usually less than 14 days, with no definitive localising symptoms or signs.


    Patients presenting with AFI should be assessed for organ dysfunction at presentation and symptoms/signs suggestive of sepsis should be ruled out as management protocol will differ.


    Most common causes of AFI have been covered below with their specific treatment options.


    Note: Patients presenting with AFI (> 2 days duration) should undergo a baseline investigation (CBC/ESR/Peripheral smear/LFT/etc) as deemed necessary by the treating physician, apart from the usual screen for common causes of tropical fever (discussed below).


    All patients with organ dysfunction should be managed inpatient.


    A) AFI (RDT- positive for P. falciparum)


    -2 RDTs 12 hour apart (if 1st RDT is negative) should be done for malaria.


    -Send Peripheral smear and QBC for malaria


    Severe Malaria: Injection Artesunate 2.4 mg/kg IV at 0, 12, 24, 48 hours


    Continue once daily till the patient is not able to accept orally


    Should be followed by oral ACT therapy


    Non-Severe Malaria: Oral ACT (Artemether/ Lumefantrine 80/480 1tab BD) for 3 days


    Radical cure: Primaquine 0.75 mg/kg single dose after ruling out G6PD deficiency


    B) AFI (RDT positive for P. Vivax)


    Severe Malaria: Injection Artesunate 2.4 mg/kg IV at 0, 12, 24, 48 hours


    Continue once daily till the patient is not able to accept orally


    Should be followed by oral therapy


    Non-severe Malaria: Chloroquine (500 mg tablet = 300 mg base)- 2 tablets stat, 1 tablet in six hours, 1 tablet once daily for two days


    Radical cure: Primaquine 0.25 mg/kg OD for 14 days after ruling out G6PD deficiency


    C) AFI (RDT negative)- Dengue or Chikungunya serology positive


    No antibiotics needed


    Remarks:


    <5 days of fever – send NS 1 antigen for Dengue


    >5 days of fever send IgM ELISA for Dengue and Chikungunya


    D) Scrub typhus:


    IFA/ ELISA for scrub typhus (>3 days of fever) for diagnosis


    Treatment: Tab/Inj doxycycline 100mg BD 7-10 days Or


    Tab/Inj azithromycin 500mg od x 5 days


    Note: Defervescence of fever with doxycycline takes only 48-72 hours.


    E) Enteric fever


    Widal may be useful for diagnosis only after the 1st week of fever, however, results need to be interpreted with caution.


    Treatment:


    Tablet Cefixime 400mg BD X 10-14 days Or


    Tablet Azithromycin 1g/day x 5 days Or


    Tablet Azithromycin 1g stat followed by 500mg/day for 6 days Or


    Ceftriaxone 1-2 g IV BD x 10-14 days


    Note: Defervescence of fever takes around 4-7 days with ceftriaxone. Consider replacing or adding azithromycin to ceftriaxone only after 4-7 days.


    F) Leptospirosis:


    Treatment:


    Tablet Doxycycline 100 mg BD x 7 days, Or


    Inj Ceftriaxone 1-2 g IV BD x 7 days


    G) Undifferentiated fever/ Fever with no localisation- Dengue or Chikungunya or Scrub or other serology negatives/ awaited/ cannot be done or Blood cultures awaited:


    Inpatient management:


    Treatment: Start with Injection Ceftriaxone 1-2 g IV BD plus Injection /oral doxycycline 100mg BD or Start with Azithromycin 1g OD


    Outpatient management:


    If clinical condition permits, to wait until the availability of reports.


    If strong clinical suspicion of bacterial infection is present, and treatment needs to be initiated:


    Treatment: Tab Cefixime 200mg BD x 5-7 days or Azithromycin 500 OD for 5 days


    Note: - Send blood culture before starting antibiotics in all patients


    - De-escalate based on specific results

    Acute Febrile IllnessAIIMSAll India Institute of Medical Sciences
    Source : All India Institute of Medical Sciences

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Dr. Kamal Kant Kohli Kohli
    Dr. Kamal Kant Kohli Kohli
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 12 Oct 2022 7:06 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok